Viridian Therapeutics, Inc. VRDN Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s operating cash flow?
- Viridian Therapeutics, Inc. (VRDN) reported operating cash flow of -$119.65M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Viridian Therapeutics, Inc.'s operating cash flow decreased by 29.1% year-over-year, from -$92.65M to -$119.65M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s operating cash flow has grown at a 50.0% compound annual growth rate (CAGR), from -$54.58M to -$276.39M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.